Effects of SPRC, SAC, PAG, PAG+SPRC and paclitaxel liposome on CSE protein expressions in SGC-7901 cells (A,B,C); gastric tumors of nude mice (D,E,F).

<p>For <b>A</b>, Lane 1, control group; Lane 2, paclitaxel liposome 10 uM; Lane 3, SPRC 1 uM; Lane 4, SPRC 10 uM; Lane 5, SAC 10 uM; Lane 6, Control group; Lane 7, SPRC 10 uM; Lane 8, PAG 10 uM; Lane 9, PAG+SPRC 10 uM. For <b>D</b>: Lane 1, control; Lane 2, paclitaxel liposome 10 mg/kg; Lane 3, SPRC 50 mg/kg; Lane 4, SPRC 100 mg/kg; Lane 5, SAC 100 mg/kg; Lane 6, control; Lane 7, SPRC 100 mg/kg; Lane 8, PAG 100 mg/kg; Lane 9, PAG+SPRC 100 mg/kg. Relative intensity is calculated by comparing with the intensity of GAPDH using densitometry (shown in the graphs on the right). * represent significant difference between control vs. SPRC, SAC and paclitaxel liposome treated groups (p<0.05). ^# represents significant difference between SPRC 10 uM vs. SPRC+PAG group. Figure <b>G</b> shows CSE activity (µmol/g) in the gastric cancer of all groups. Figure <b>H</b> shows H₂S levels (µM) in cell culture media. Figure <b>I</b> show plasma H₂S levels in gastric tumors of nude mice of different groups.</p

Morphological analyses of SGC-7901 cells.

<p><b>A.</b> treatment with SPRC, SAC, PAG, PAG+SPRC and paclitaxel liposome (10 uM) in 24 h for determination of apoptotic changes analyzed under a fluorescence microscope. <b>B.</b> Analysis of apoptotic cells by Flow cytometric assay. <b>C.</b> Cell cycle distribution. Markers on pictures indicate: 1, Control. 2, SPRC 10 uM. 3. SAC 10 uM. 4. PAG 10 uM. 5. SPRC+PAG, each 10 uM. 6. Paclitaxel liposome 10 uM.</p

Growth inhibition of SGC-7901 cells under SPRC treatment.

<p><b>A.</b> Dose-response study of the effects of SPRC on growth inhibition of SGC-7901 cells. <b>B.</b> Effects of SPRC, SAC, PAG, PAG+SPRC and paclitaxel liposome on viability of SGC-7901 cells. <b>C.</b> Effects of SPRC, SAC, PAG, PAG+SPRC and paclitaxel liposome on colony formation in SGC-7901 cells. <b>D.</b> Effects of SPRC, SAC and paclitaxel liposome on migration ability of SGC-7901 cells. Differential cell migration ability was examined by the wound-closure assay. <b>E.</b> Effects of SPRC, SAC and paclitaxel liposome on wound closure speed. Values are expressed as % of control. * represent significant difference between control vs. SPRC, SAC and paclitaxel liposome groups (p<0.01). ^# represent significant difference (p<0.01) between SPRC vs SPRC+PAG group (p<0.01).</p

Effects of intra-peritoneal administration of SPRC, SAC and paclitaxel liposome on gastric cancer growth in male nude mice.

<p><b>A.</b> Change in average tumor volume (mm³). <b>B.</b> Inhibition rate (IR) on tumor growth at different days. <b>C.</b> Change in tumor weight. <b>D.</b> Change in tumor size. <b>E. </b><i>In vivo</i> tumor imaging of nude mice after treatment for 24 days. * represent significant difference (p<0.05) between control vs. SPRC, SAC and paclitaxel liposome treated groups. <b>^#</b>represents significant difference (p<0.05) between SPRC 100 mg/kg vs. SPRC+PAG and PAG treated groups. <b>F.</b> H.E. staining with amplification of 4×10 and larger amplified pictures (100×10) at right corner. <b>G.</b> Tunnel staining (100×10) of apoptotic bodies of gastric tumors. Number markers on pictures indicate: 1, control group; 2, paclitaxel liposome 10 mg/kg group; 3, SPRC 50 mg/kg group; 4, SPRC 100 mg/kg group; 5, SAC 100 mg/kg group.</p